ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Provided By GlobeNewswire
Last update: Nov 12, 2025
Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled
PMN310 continues to demonstrate a favorable safety profile
On track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026
9.1
+0.97 (+12%)
Find more stocks in the Stock Screener
PMN Latest News and Analysis
